Steris Earnings Call: Growth Holds, Tariffs Bite
Steris ((STE)) has held its Q3 earnings call. Read on for the main highlights of the call.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
STERIS’ latest earnings call struck a cautiously upbeat tone, showcasing resilient growth and EPS expansion despite mounting cost pressures. Management underscored strong demand across key segments and a healthy backlog, while openly acknowledging margin compression from tariffs and inflation. Investors heard a story of solid fundamentals tempered by near‑term profitability headwinds.
Top-Line Growth
STERIS delivered robust third-quarter revenue performance, with total as‑reported sales up 9%. Constant currency organic revenue rose 8%, driven primarily by higher volumes and roughly 200 basis points of pricing, signaling that underlying demand remains intact and the company is successfully passing through at least some cost inflation.
Earnings and EPS Expansion
Adjusted net income from continuing operations reached $249.4 million, translating into adjusted diluted EPS of $2.53. That represented a 9% year‑over‑year increase, demonstrating that earnings are still growing faster than the top line even as tariffs and inflation weigh on margins, and reinforcing management’s confidence in its full‑year outlook.
AST Capital Equipment Strength
The AST segment was a standout, with constant currency organic revenue climbing 8% on the back of a dramatic 103% year‑over‑year surge in capital equipment sales. Segment profitability improved as AST EBIT margin ticked up 30 basis points to a hefty 45.1%, underscoring the high‑margin nature of this business and its importance to the overall profit mix.
Service and Consumables Momentum
Recurring revenue remained a key pillar, with healthcare services up 11% and consumables rising 8% in the quarter. Life Sciences posted an 11% gain in consumables and 5% constant currency organic revenue growth, illustrating resilient demand for procedure‑driven services and steady utilization of sterilization and infection prevention products.
Backlog and Capital Stability
Visibility into future revenue remains strong, supported by a healthcare capital equipment backlog above $400 million. Life Sciences backlog stayed over $100 million as well, suggesting a solid pipeline of projects that should support continued growth and provide some cushion against near‑term volatility in order patterns.
Maintained Full-Year Guidance
Management maintained its fiscal 2026 outlook, including roughly 8% to 9% as‑reported revenue growth and 7% to 8% constant currency organic revenue growth. The company also reaffirmed adjusted diluted EPS guidance around $10.00 to $10.30, while cautioning that the high end is less likely due to additional tariff headwinds built into the model.
Balance Sheet and Leverage
STERIS ended the quarter with $1.9 billion in total debt and gross debt to EBITDA of about 1.2 times. This modest leverage profile gives the company ample flexibility to pursue strategic investments or acquisitions while still preserving balance sheet strength and supporting ongoing capital deployment priorities.
Cash Flow and Capital Discipline
Year‑to‑date capital expenditures totaled $278.8 million against depreciation and amortization of $363.1 million, reflecting continued investment but at a more measured pace. Management highlighted improved free cash flow compared with the prior year, crediting higher earnings and lower capital spending as it keeps a disciplined stance on cash deployment.
Operational Actions and Mitigation
To counter rising costs, STERIS is actively pursuing tariff mitigation strategies, including shifting suppliers, negotiating with partners, and exploring alternative sourcing options. The company is also focusing on productivity and efficiency initiatives, aiming to recapture margin over time and blunt the impact of external inflationary pressures.
Margin Pressure and Gross Margin Decline
Despite pricing and productivity gains, profitability took a hit as gross margin fell 70 basis points year‑over‑year to 43.9%. Management pointed to higher tariffs and inflation as the main culprits, indicating that cost increases currently outpace mitigation efforts and are likely to remain a near‑term overhang on margins.
EBIT Margin Compression Across Segments
Company‑wide EBIT margin slipped 40 basis points to 22.9% of revenue, reflecting the cumulative impact of cost pressures. Healthcare EBIT margin declined 100 basis points to 24.3%, while Life Sciences margins eased 20 basis points, showing that no major business line is fully immune to the current inflation and tariff environment.
Tariff Headwinds
Tariffs remain a significant drag, with about $16 million of pretax impact in the quarter and a modeled annual run rate of roughly $55 million. Management expects around $10 million of additional tariff burden, which it said makes hitting the top end of the EPS guidance range less likely, even as underlying demand trends remain supportive.
Near-Term Softness and Tough Comparisons
Executives warned of seasonal slowing in the second half and particularly challenging fourth‑quarter comparisons, especially in AST capital equipment after last year’s strength. They also foresee some continued deceleration in healthcare services growth relative to earlier in the year, reinforcing a more cautious stance on near‑term momentum.
Orders and Demand Volatility
Order patterns show some nuance, with healthcare orders down 1% year‑to‑date against a strong prior‑year base. AST services experienced notable month‑to‑month swings, including a weak October followed by recovery by December, suggesting underlying demand is intact but subject to short‑term volatility and timing noise.
Tariff Exposure and Capital Mix
Management noted that higher metals tariffs and a mix shift toward capital equipment are amplifying tariff exposure as capital sales grow. While this mix is positive for revenue and long‑term installed base, it heightens near‑term margin risk and puts added importance on successful mitigation and pricing strategies.
Conservative Q4 Cash Flow Execution
While maintaining free cash flow guidance at $850 million, STERIS struck a conservative note on fourth‑quarter cash generation. Management cited timing factors, a heavy capital spending quarter, and typical seasonality and weather dynamics as reasons for caution, even though year‑to‑date trends remain favorable.
Forward-Looking Guidance and Outlook
Looking ahead, STERIS reiterated its fiscal 2026 framework of high single‑digit revenue growth and adjusted EPS around $10.00 to $10.30, alongside expected free cash flow of $850 million and planned CapEx of $375 million. Tariffs are embedded as a sizeable ongoing cost, but the company expects volume growth, pricing, and productivity to support continued EPS expansion over time.
STERIS’ earnings call painted a picture of a company balancing solid growth and healthy finances against stubborn cost headwinds and short‑term volatility. Revenue and EPS trends, strong segment performance, and a robust backlog underpin a constructive longer‑term story, even as margin pressure and tariffs keep expectations anchored more toward disciplined execution than aggressive upside surprises.
